Kamil Kuca

Kamil Kuca

Auto-generated profile, based on publicly available information

Kamil Kuca

Faculty of Military Health Sciences, Hradec Kralove, Czech Republic

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2015 in Molecules
Verified
Journal Article
Open access
PDF file
Jan KorabecnyJan Korabecny
Jan Korabecny
MAMartin Andrs
Martin Andrs
Eugenie  NepovimovaEugenie Nepovimova
Eugenie Nepovimova
RDRafael Doležal
Rafael Doležal
KBKaterina Babkova
Katerina Babkova
KKKamil Kuca
Kamil Kuca
Alzheimer’s disease (AD) is a debilitating progressive neurodegenerative disorder that ultimately leads to the patient’s death. Despite the fact that novel pharmacological approaches endeavoring to block the neurodegenerative process are still emerging, none of them have reached use in clinical practice yet. Thus, palliative treatment represented by acetylcholinesterase inhibitors (AChEIs) and memantine are still the only therapeutics used. Following the multi-target directed ligands (MTDLs) strategy, herein we describe the synthesis, biological evaluation and docking studies for novel 7-methoxytacrine-p-anisidine hybrids designed to purposely target both cholinesterases and the amyloid cascade. Indeed, the novel derivatives proved to be effective non-specific cholinesterase inhibitors showing non-competitive AChE inhibition patterns. This compounds’ behavior was confirmed in the subsequent molecular modeling studies.

1 March 2010 in Current Bioactive Compounds
Verified
Journal Article
Closed access
PDF file
JBJiri Bajgar
Jiri Bajgar
KKKamil Kuca
Kamil Kuca
JFJosef Fusek
Josef Fusek
DJDaniel Jun
Daniel Jun
LBLucie Bartosova
Lucie Bartosova
Prophylaxis against nerve agent intoxication is based on various approaches: Keeping AChE, key enzyme for toxic action of OP/nerve agents intact (protection of cholinesterases) is a basic requirement for effective prophylaxis. Detoxification realised by administration of the enzymes splitting the OP or evaluating specific enzymes (cholinesterases) is another possibility (scavenger effect). The antidotes currently used for the treatment of OP poisoning including reactivators are to be tested as prophylactics. This principle can be considered as a “treatment in advance”. Moreover, they are uneffective when administered alone; their effect is potentiated when they are administered with anticholinergics. Transdermal administration of reactivator HI-6 was used and prophylactic antidote TRANSANT was developed and introduced into the Czech Army. At present, PYRIDOSTIGMINE seems to be common prophylactic antidote; prophylactics PANPAL (tablets with pyridostigmine, trihexyphenidyle and benactyzine), TRANSANT (transdermal patch containing HI-6) are other means introduced into different armies as prophylactics. TRANSANT is only one prophylactics evaluating reactivator. When administered simultaneously with PANPAL, prophylactic efficacy is increased and represents the best prophylaxis at present.

15 June 2013 in African Journal of Pharmacy and Pharmacology
Verified
Journal Article
Open access
PDF file
ZKZdarova Karasova
Zdarova Karasova
JKJana Zdarova Karasova
Jana Zdarova Karasova
Jan KorabecnyJan Korabecny
Jan Korabecny
FZFilip Zemek
Filip Zemek
VHVendula Hepnarova
Vendula Hepnarova
KKKamil Kuca
Kamil Kuca
Although the information about Alzheimer’s disease (AD) etiology is still unclear; acetylcholinesterase inhibitors still play a major role in symptomatic treatment of AD. Unfortunately, a relevant argumentation is complicated since information about real drug concentration in the brain or time-dependent blood-brain barrier (BBB) distribution studies are still quite rare. In this in vitro study, high-performance liquid chromatography (HPLC) method with special (IAM – immobilized artificial membrane) column was used to determine the ability of cholinesterase inhibitors to penetrate through BBB. Set of 8 structurally different cholinesterase inhibitors applicable to AD treatment was evaluated throughout this study. According to our method, all molecules are able to penetrate BBB by passive transport. However, some molecules such as huperzine A and galanthamine have lower ability to penetrate the BBB directly. These molecules may be delivered into the brain via active transport. Other molecules probably use passive transport to permeate into the central nervous system; tacrine and 7-methoxytacrine exert the highest passive permeation from this set of compounds. Key words: Blood-brain barrier, central nervous system, acetylcholinesterase, Alzheimer disease.


1 January 2013
Verified
Journal Article
Closed access
JBJan Bures
Jan Bures
JKJaroslav Kvetina
Jaroslav Kvetina
MPMichal Pavlik
Michal Pavlik
MKMartin Kunes
Martin Kunes
MKMarcela Kopacova
Marcela Kopacova
ITIlja Tacheci
Ilja Tacheci